scPharmaceuticals Stock (NASDAQ:SCPH)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$2.32

52W Range

$1.94 - $5.65

50D Avg

$3.01

200D Avg

$3.91

Market Cap

$129.73M

Avg Vol (3M)

$460.36K

Beta

0.38

Div Yield

SCPH Company Profile

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

162

IPO Date

Nov 17, 2017

Website

SCPH Performance

SCPH Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$36.33M	$13.59M	-
Operating Income	$-64.78M	$-55.40M	$-36.16M
Net Income	$-85.15M	$-54.81M	$-37.52M
EBITDA	$-64.78M	$-46.06M	$-33.07M
Basic EPS	$-1.91	$-1.42	$-1.32
Diluted EPS	$-1.91	$-1.42	$-1.32

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 19, 25 | 4:30 PM

Q3 24Nov 13, 24 | 4:30 PM

Q2 24Aug 15, 24 | 4:30 PM

Peer Comparison

Ticker	Company
MIST	Milestone Pharmaceuticals Inc.
IOVA	Iovance Biotherapeutics, Inc.
LYRA	Lyra Therapeutics, Inc.
ONCY	Oncolytics Biotech Inc.
MNPR	Monopar Therapeutics Inc.
DMAC	DiaMedica Therapeutics Inc.
MCRB	Seres Therapeutics, Inc.
CNTA	Centessa Pharmaceuticals plc
KTTA	Pasithea Therapeutics Corp.